Revenue: As of FY2025, the actual value is USD 44.52 M.EPS: As of FY2025, the actual value is USD -0.19.EBIT: As of FY2025, the actual value is USD -2.773 M.<h4>Revenue</h4><ul><li>Fourth Quarter 2025 Net Revenues: 坎伯兰药业 (Cumberland Pharmaceuticals Inc.) reported net revenues of $13.7 million for the fourth quarter of 2025, representing a 31% increase over the prior year period .</li><li>Full Year 2025 Net Revenues: Net revenues for the full year 2025 were $44.5 million, an 18% increase over the prior year, meeting the company’s double-digit revenue growth target . This compares to $37,867,945 in net revenues for the full year 2024 .</li><li>2025 Product-Specific Net Revenues: The 2025 net revenues included $10.5 million for Kristalose®, $11.9 million for Sancuso®, $9.5 million for Vibativ®, $4.7 million for Caldolor®, and $3.3 million for Talicia® .</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss: The net loss for 2025 was - $2.9 million, an improvement of $3.6 million from the prior year . The net loss attributable to common shareholders was - $2,836,128 for 2025, compared to - $6,479,770 for 2024 .</li><li>Adjusted Earnings: Adjusted Earnings for the full year 2025 were $1.7 million, representing a $2.7 million improvement over the prior year . For 2025, Adjusted Earnings were $1,748,308, compared to - $990,865 for 2024 .</li><li>Operating Expenses: Total operating expenses for 2025 were $47.3 million, compared to $44,300,354 for 2024 .</li><li>Operating Loss: The operating loss for 2025 was - $2,791,993, an improvement from an operating loss of - $6,432,409 in 2024 .</li></ul><h4>Cash Flow</h4><ul><li>Cash Flow from Operations: Cash flow from operations was $4.9 million in 2025, a $5.5 million increase over 2024 . Net cash provided by operating activities was $4,932,522 in 2025, compared to net cash used in operating activities of - $612,186 in 2024 .</li><li>Net Cash from Investing Activities: Net cash used in investing activities was - $4,706,497 in 2025, compared to net cash provided by investing activities of $57,842 in 2024 .</li><li>Net Cash from Financing Activities: Net cash used in financing activities was - $6,745,516 in 2025, compared to net cash provided by financing activities of $196,904 in 2024 .</li><li>Cash and Cash Equivalents: 坎伯兰药业 (Cumberland Pharmaceuticals Inc.) ended 2025 with $11,444,693 in cash and cash equivalents, a decrease from $17,964,184 at the beginning of the year .</li></ul><h4>Balance Sheet</h4><ul><li>Total Assets: As of December 31, 2025, total assets were $76.8 million, compared to $75,583,410 at the end of 2024 .</li><li>Total Liabilities: Total liabilities were $52.3 million as of December 31, 2025, compared to $53,037,433 at the end of 2024 .</li><li>Shareholders’ Equity: Total shareholders’ equity was $24.9 million on December 31, 2025, compared to $22,853,494 at the end of 2024 .</li><li>Debt Reduction: The company’s credit facility balance of $5.2 million represented a reduction of $10 million in debt compared to the end of 2024 .</li></ul><h4>Unique Metrics and Operational Highlights</h4><ul><li>International Expansion: 坎伯兰药业 (Cumberland Pharmaceuticals Inc.) received regulatory approval for its Vibativ® product in China in February 2025 and launched Vibativ in Saudi Arabia in September 2025 . Its ibuprofen injection product also received regulatory approval in Mexico in October 2025 .</li><li>Commercial Portfolio Expansion: In October 2025, the company announced a co-commercialization agreement with RedHill Biopharma Ltd. for Talicia®, an FDA-approved oral capsule for H. pylori infection, adding it to its commercial product portfolio .</li><li>Reimbursement Milestone: Caldolor® received a permanent J-code (J1741) in December 2025, establishing a CMS reimbursement price that enhances provider access to this non-opioid pain and fever management option .</li><li>Clinical Trial Results (ifetroban): Early 2025 saw positive top-line results from the FIGHT DMD clinical trial evaluating ifetroban for Duchenne muscular dystrophy (DMD) heart disease, showing a 3.3% overall improvement in left ventricular ejection fraction (LVEF) with high-dose ifetroban . The DMD program received Orphan Drug and Rare Pediatric Disease designations in late 2024 and Fast Track Designation in early 2026 from the FDA .</li></ul><h4>Outlook / Guidance</h4>No specific outlook or guidance content was provided in the reference text .

Cumberland Pharma | 8-K: FY2025 Revenue: USD 44.52 M